HUJI MGC Pharma DC3: Skin disorders

Project 1: Nanodelivery of cannabinoids for psoriasis

The body’s protective system against stress in general is mediated by a unique biochemical pathway known as the Nrf2-Keap1 pathway. We hypothesized that cannabinoids and polyphenols derived from the cannabis plant (Cannabis sativa) are excellent candidates for activation of this pathway and providing cutaneous protection against stress. We also intend to develop unique skin nanodelivery system to target cannabinoids to affect local cutaneous pathologies (such as psoriasis) and Nrf2 pathway.

Supervisors: Prof. Ron Kohen (HUJI) and A/Prof. Nitin Manti (RMIT), Dr Francesca Cavalieri (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)

 

Project 2: Nanodelivery of cannabinoids for melanoma

We will design various nanometric carries to deliver cannabinoids to skin and monitor their dermal distribution using novel mass spectrometry imaging. We aim at topical delivery of cannabinoids to different skin strata for the treatment of melanoma. The effect of nanocarriers on the distribution of cannabinoids in the skin will be evaluated by mass spectrometry imaging, which allows simultaneous mapping of drugs, delivery vehicles, and endogenous molecules in skin strata.

Supervisors: Dr. Katy Margulis (HUJI) and A/Prof. Nitin Manti (RMIT), Dr Francesca Cavalieri (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)   

 

Project 3: Nanodelivery of cannabinoids against biofilm

We will evaluate antibiofilm mode of action of selected Endocannabinoids (ECs) and Cannabinoids (CA), incorporated in nano delivery system. Our preliminary data show that several ECs and CA exhibited antibiofilm effect against pathogenic bacteria including antibiotic resistant antibiotics. Therefore, we will screen antibiofilm effects of ECs CAs on bacteria/fungi biofilm models, and understand the mode of action of these agents for the pharmacological evaluation.

Supervisors: Prof. Doron Steinberg (HUJI) and A/Prof. Nitin Manti (RMIT) , Dr Francesca Cavalieri (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)    

Share on facebook
Share on twitter
Share on linkedin
Share on email

Reference

HUJI MGC Pharma DC3

Research Areas

Biomedical sciences, Applied science, Biotechnology and biological sciences, Nanotechnology and Pharmacy, Chemistry

Research Host

Hebrew University of Jerusalem (HUJI)

PhD awarding institution/s

Hebrew University of Jerusalem (HUJI) - RMIT University

Location

Israel

Status

Open Position

RMIT University

Other Positions

Supervisors

Associate Prof. Andrey Molotnikov (RMIT), Professor Dr.-Ing. Thomas Niendorf (UoK), Philipp Krooss (UoK) and Dr. Markus Weinmann (UoK)

PhD awarding institution/s

University of Kassel (UoK) and RMIT University

Location

Germany

Status

Open Position

Supervisors

Prof. Jenny Zhang (RMIT) and Prof. Jose Antonio Vilar-Fernandez (UDC) and José Luis González Leal (Navantia) and Prof. Amparo Alonso-Betanzos (UDC) and Prof. Vicente Díaz-Casas (UDC) and Prof. Marcos Miguez González (UDC)

PhD awarding institution/s

University of A Coruña (UDC) and RMIT University

Location

Spain

Status

Open Position

Supervisors

Prof. Anne-Laure Mention (RMIT) and Associate Prof. Carsten Nico Hjortso (UPCH) and Dr. Marie Smed (UPCH)

PhD awarding institution/s

University of Copenhagen (UCPH) and RMIT University

Location

Denmark

Status

Open Position

RMIT and many of the REDI partners are HSR4R certified
europe-1-1.svg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101034328.

Results reflect the author’s view only. The European Commission is not responsible for any use that may be made of the information it contains